DOCM.SW DocMorris AG (SIX) intraday CHF4.57: earnings 19 Mar 2026 may reset valuation

DOCM.SW stock trades at CHF4.57 intraday after a recent slide as investors position ahead of the 19 Mar 2026 earnings release. The shares are down 3.71% today, with volume at 56,619.00 ahead of the report. We review near-term catalyst areas that could move the stock when DocMorris AG reports results on SIX.

Earnings catalyst: what to watch in DOCM.SW stock

DocMorris AG reports on 19 Mar 2026. Investors will watch revenue growth, gross margin, and any update to guidance. One clear metric to monitor is operating cash flow per share, currently -2.42 CHF.

Expect questions on the Swiss retail pharmacy mix and cross-border mail-order trends. Management comments on margins and cost control should drive intraday moves when the report lands.

Price action and technicals for DOCM.SW stock

DOCM.SW stock opened at CHF4.60 and trades between CHF4.42 and CHF4.60 intraday. The 50-day average is CHF5.62 and the 200-day average is CHF6.22, highlighting shorter-term weakness.

Technicals show RSI 24.65 (oversold) and ADX 26.70 (strong trend). Volume today is 56,619.00, below the 3-month average of 275,728.00. These indicators suggest elevated volatility into earnings.

Fundamentals and valuation of DOCM.SW stock

DocMorris AG has market capitalization CHF218,404,998.00 and shares outstanding 48,599,243.00. Trailing EPS is -4.58 CHF and the P/E is -0.98, reflecting losses.

Key ratios: price-to-sales is 0.21, price-to-book is 0.27, and current ratio is 3.25. These figures show a low valuation on sales but continued negative profitability. Cash per share stands at 7.89 CHF.

Meyka AI grade and price forecast for DOCM.SW stock

Meyka AI rates DOCM.SW with a score out of 100: 63.74, Grade B, Suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a quarterly fair price of CHF5.56, implying 21.75% upside from the current CHF4.57. Forecasts are model-based projections and not guarantees. Use the CHF6.22 200-day average and the year low CHF4.42 as technical reference points.

Risks and opportunities for DOCM.SW stock

Risks include continued net losses, reflected in EPS -4.58 CHF, and margin pressure from competitive pricing. The company’s negative free cash flow per share of -2.48 CHF raises funding risk if momentum stalls.

Opportunities include recovery in e-pharmacy volumes, cross-border expansion, and cost discipline. A stronger operating cash flow print on the earnings call would be a clear positive trigger.

Trading strategy and sector context for DOCM.SW stock

Healthcare peers trade at an average P/E around 29.59; DocMorris’s negative P/E contrasts starkly. Position sizing should reflect elevated volatility and the stock’s history of steep moves.

Traders can use the earnings date to set event-driven plays with tight stops. Long-term investors should weigh valuation metrics and cash per share 7.89 CHF against operating losses.

Final Thoughts

DOCM.SW stock trades at CHF4.57 intraday as markets price in earnings on 19 Mar 2026. The key near-term drivers are revenue trends, margin commentary, and operating cash flow. Our Meyka AI grade places DOCM.SW at 63.74 (Grade B, HOLD), reflecting mixed fundamentals and a model-based opportunity. Meyka AI’s forecast model projects a quarterly level of CHF5.56, implying 21.75% upside versus the current price. Use the CHF6.22 200-day average as an upside technical target and CHF4.42 year low as a downside reference. Forecasts are model-based projections and not guarantees. Check the official report and management comments at the release for intraday catalysts and trade plan adjustments. For the company profile and investor materials visit the corporate site and our Meyka stock page for live updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.